SLC9A1 and Duchenne muscular dystrophy: In terms of Rimeporide (EMD-87580), it has a similar half-life of 3–4 h to HOE642 and has recently been tested as a first-in-class NHE1 inhibitor in a phase Ib clinical trial for Duchenne muscular dystrophy (DMD) [27].